SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

etavopivat

NVO·NOVO NORDISK A S
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 3 (completed pivotal trial)
Time to market
Regulatory submission to the FDA is expected imminently (H2 2026). If filed, a standard FDA review would take approximately 6-12 months, suggesting a potential approval decision in the second half of 2027 at the earliest.
Why 4/10
The next hard catalyst is the regulatory submission to the FDA, which Novo Nordisk has said it plans to make in the second half of 2026 (now imminent as of November 2026). However, no PDUFA date has been set, and the drug is a very small part of Novo Nordisk's massive GLP-1-dominated business, so impactScore is capped at 4.
Actionable Insight NEUTRAL

Watch for Novo Nordisk's regulatory submission of etavopivat to the FDA, expected in the second half of 2026 (imminent). If filed, a PDUFA date would be set roughly 6-12 months later. The key competitive dynamic is Agios' mitapivat, which has a PDUFA date of February 1, 2027 for the same sickle cell indication. Etavopivat's once-daily dosing could be a differentiator versus mitapivat's twice-daily regimen.

Price Chart

Loading chart...

Executive Summary

Etavopivat (formerly FT-4202) is Novo Nordisk's investigational once-daily oral pill for sickle cell disease, acquired through the $1.1 billion purchase of Forma Therapeutics in 2022. In April 2026, the pivotal Phase 3 HIBISCUS trial met both co-primary endpoints: a 27% reduction in painful vaso-occlusive crisis events and a 48.7% hemoglobin response rate at 24 weeks (vs 7.2% on placebo). Novo Nordisk plans to submit for first regulatory approval in the second half of 2026, with filings reportedly being prepared as of early November 2026. The drug competes directly with Agios' mitapivat, which has a PDUFA date of February 1, 2027 for the same indication. Etavopivat is a small part of Novo Nordisk's massive, GLP-1-dominated business, so even a successful approval would have limited impact on NVO's share price.

How It Works

Etavopivat is an oral pill taken once daily that activates an enzyme called pyruvate kinase-R (PKR) inside red blood cells. This activation boosts the cells' energy (ATP) and lowers a substance called 2,3-DPG, which together make the red blood cells healthier and less likely to deform into the sickle shape that causes painful blockages in blood vessels. It is designed to treat sickle cell disease, an inherited blood disorder where misshapen red blood cells clog vessels, causing severe pain episodes and organ damage.

Trial Status

The pivotal Phase 2/3 HIBISCUS trial (NCT04624659) met both co-primary endpoints in April 2026. A Phase 3b trial (HIBISCUS2) and an open-label extension (FLORAL, NCT06609226) are ongoing. A Phase 2 study in thalassemia (GLADIOLUS, NCT04987489) is ongoing. A Phase 2 study in myelodysplastic syndromes was terminated.

The Two-Sided Case

▲ Bull Case4
Etavopivat met both co-primary endpoints in the pivotal Phase 3 HIBISCUS trial: a 27% reduction in vaso-occlusive crisis events and a 48.7% hemoglobin response rate at week 24 (vs 7.2% placebo), establishing proof of concept as a potential first-in-class oral PKR activator for sickle cell disease.
Once-daily oral dosing is a convenience advantage over competitor mitapivat (Agios), which requires twice-daily dosing, potentially improving patient adherence.
Novo Nordisk acquired etavopivat via the $1.1 billion Forma Therapeutics acquisition in 2022, and the positive Phase 3 data validates that acquisition thesis, with regulatory filings being prepared for H2 2026.
The global sickle cell disease treatment market is projected to grow from $4.73 billion in 2026 to $20.47 billion by 2034 (CAGR 20.1%), providing a large addressable market for a novel oral therapy.
▼ Bear Case4
Etavopivat has not yet been submitted for FDA review as of November 2026, while competitor Agios' mitapivat already has a PDUFA date of February 1, 2027 for sickle cell disease, meaning mitapivat could reach the market first.
The 27% reduction in vaso-occlusive crises, while statistically significant, is modest and may face reimbursement or prescriber adoption challenges versus existing and emerging therapies.
Etavopivat is a very small part of Novo Nordisk's overall business (dominated by GLP-1 diabetes/obesity franchise), so even a successful approval would have limited impact on NVO's share price.
A Phase 2 study of etavopivat in myelodysplastic syndromes (MDS) was terminated, narrowing the drug's potential addressable market beyond SCD and thalassemia.

Upcoming Catalysts

  • Regulatory submission to the FDA (expected H2 2026, imminent)
  • Detailed Phase 3 HIBISCUS results presentation at a scientific conference
  • Potential PDUFA date assignment following FDA submission
  • HIBISCUS2 (Phase 3b) topline readout
  • FLORAL open-label extension safety data

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVO NORDISK A S 6-K NVO ·Originating report

Sources · 8

Hover a chip for the title
1 biospace.com2 pharmaphorum.com3 hcplive.com4 biospace.com5 businesswire.com6 ashpublications.org7 fortunebusinessinsights.com8 fiercebiotech.com